CTVACorteva
- Next report
- No date yet
- none in the next 8 weeks
- Price
- $9.74
- −19.77% today · $60.5B cap
Past and upcoming reports
1
| Nov 11, 2026 | Sep 30, 2026 | After the market closes | $0.09 | not recorded |
After the report
Nov 11, 2026 report
CTVA fell 0.49% after the reported print, while earnings detail and forward guidance remained unavailable.
Corteva traded at $12.11, down $0.06, on 13.2 million shares after the November 11 report. Reported EPS, guidance, and post-earnings news were not captured, so the immediate signal is price weakness rather than a confirmed earnings beat or miss. The stock remained below its 20-day SMA of $12.18 and its one-month return was -9.13%.
Reported against expected
Reported EPS was unavailable. The $0.09 consensus estimate was pre-print context only. no beat or miss can be confirmed.
Guidance
Management guidance was not captured, and no post-earnings news items were available.
How the stock reacted
CTVA closed at $12.11, down $0.06 or 0.49%, with 13.2 million shares traded. event-day reaction percentages were unavailable.
What changed
CTVA declined 0.49% to $12.11 after the November 11 print, versus $12.17 previously.
What the price now assumes
The price below its $12.18 20-day SMA signals caution despite a 19.41% next-year EPS-growth forecast.
What it means for the business
Keep a neutral-to-cautious bias. upgrade only if post-spin reassessment produces measurable profit-growth evidence.
The next one to three months, as we saw it then
Better case30%
A favorable post-spin analyst reassessment could support recovery if Corteva converts structural simplicity into faster earnings growth.
Base case45%
CTVA remains range-bound as investors weigh low reported growth against a simpler structure and prospective earnings improvement.
Worse case25%
Weak profit conversion could keep pressure on the shares, particularly after a -9.13% one-month performance and sub-$12.18 technical position.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Enter only after post-spin analyst reassessment improves forward earnings evidence. no-trade while EPS, guidance, and post-earnings news remain unavailable.
Scenario odds are a judgement, not measured.